July 2023 Global Innovative Drug Report 

Leveraging insights from our AI-powered life sciences intelligence platform Synapse, we’re delighted to present our July 2023 Global Innovative Drug Report.

This report offers a comprehensive overview of the latest advancements in the pharmaceutical industry and an analysis of each selected drug. It provides a snapshot of each drug and explores its R&D status, active patents, mechanisms of action, clinical trials, competitive landscape, and other pertinent factors.

The report consists of four parts: 

1. First Approved Drugs in July 

2. New Drug Analysis 

3. Global Drugs under Expedited Review Pathway in July 

4. Analysis of Selected ERP Drugs 

Global Innovative Drug Report Overview 

1.) First Approved Drugs in July 

In July 2023, four drugs received global approval: a prophylactic vaccine, a small molecule drug (SMD), a monoclonal antibody, and a herbal medicine.

2.) New Drug Analysis

This report highlights two recently approved drugs, with a spotlight on CYFENDUS.

3.) Global Drugs Under Expedited Review Pathway in July 

In July 2023, a total of 41 drugs globally were on Expedited Review tracks. This includes 19 with Orphan Drug designations, eight designated as Breakthrough Therapies, seven on the Fast Track, four under Priority Review, two with Conditional Marketing Approvals, two targeting Rare Pediatric Diseases, and one as a Qualified Infectious Disease Product.

4.) Analysis of Selected ERP Drugs 

In this report, we’ve chosen to analyze seven drugs from the Expedited Review Pathway. Specifically, for Zenocutuzumab, the report explores the following aspects:

Gain Access to the Comprehensive Report for FREE – Download Now! If you aren’t registered for Synapse (registration is required to download the report), click here to register for free.

Patsnap Synapse Database: An Overview and Key Features

Discover the innovative PatSnap Synapse database – an AI-powered platform that provides intuitive interfaces, curated content, and access to massive information sources. With integrated access to company data, diseases, targets, clinical studies, and biological and chemical entities, our platform offers a powerful search and association experience. Sign up for free today and experience the benefits for yourself!

R&D Decision Makers

Our mission is to empower R&D decision makers with swift access to accurate and connected data, facilitating their understanding of emerging technology trends, competitive landscapes, and partnership opportunities. By providing comprehensive insights, our platform helps decision makers to navigate and steer the direction of innovation with confidence.

Business Development Professionals 

We offer a comprehensive database that covers the drug pipeline and investment history for over 320,000 life science organizations. This invaluable resource allows you to make informed decisions regarding potential partnerships or acquisition targets with confidence. Gain access to our extensive database and unlock the insights you need to drive your business forward.

Pharmaceutical Analyst 

Our platform is designed to accelerate the research process for pharmaceutical analysts by leveraging a wealth of connected data, including drug approvals, clinical trials, patents, non-patent literature, and news. With Synapse, users gain a comprehensive 360-degree view of the competitive and technological landscape, empowering them to make informed decisions quickly and efficiently. Discover the power of Synapse and revolutionize your research today.

Copyright Statement: This report is the sole property of Patsnap and is protected under copyright laws. Any reproduction, excerpting, or other use of this report without explicit authorization from Patsnap is strictly prohibited. Authorized products must be used within the scope of authorization and must include a clear indication of the source. Patsnap reserves the right to investigate any violations of this statement and pursue legal action as necessary. For inquiries regarding authorization, please contact [email protected].